Alkermes CEO: Good Time to Make Meds

  Richard Pops, Alkermes CEO, says it's a good time to be developing new medicines if you have access to capital. "Biotech industry is the lifeblood-- the wells spring-- of new innovation for the big pharmaceutical companies," he says.

Supreme Court Decision: What's At Stake for Big Pharma?

  Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.

'The Hansen Files': Drug Trials, Part 2

  To see whether private drug-testing review boards are approving plans that are scientifically safe and run by qualified doctors, Dateline creates a fictitious pharmaceutical company. We propose testing a drug identical to one already withdrawn from the market because of serious safety concerns.